GlycoMimetics Inc. (GLYC)

Business: GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States.

IPO Date: 10-Jan-2014

CEO, Pres & Director: Mr. Harout Semerjian

Sr. VP & CFO: Mr. Brian M. Hahn

Listing: NASDAQ: GLYC

Country: United States

Headquarters: Rockville, MD

Website: https://www.glycomimetics.com

Market cap: $32.25 Mln

Revenue (TTM): $0.09 Mln

Earnings (TTM): $-63.81 Mln

Cash: $76.52 Mln

Total Debt: $1.68 Mln

Insider's Holding: 1.98%

Liquidity: Low

52 Week range: $0.51 - 2.50

Shares outstanding: 52,392,400

10 Years Aggregate:

• CFO: $-290.08 Mln
• EBITDA: $-258.55 Mln
• Net Profit: $-316.55 Mln